Humanigen

Humanigen, Inc. is a clinical-stage biopharmaceutical company that specializes in developing proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's primary product, Lenzilumab, targets and neutralizes granulocyte-macrophage colony-stimulating factor and is currently undergoing Phase Ib/II clinical trials for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. Additionally, Humanigen is developing Ifabotuzumab, which targets the EphA3 receptor and has completed the Phase I dose escalation phase for multiple hematologic malignancies, and HGEN005, an anti-EMR1 monoclonal antibody in pre-clinical development for eosinophilic diseases. The company is engaged in collaborations to advance its research, including a partnership with Kite Pharma for a multi-center study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma, as well as a cooperative agreement with the Department of Defense for potential COVID-19 treatment applications. Founded in 2000 and based in Burlingame, California, Humanigen was previously known as KaloBios Pharmaceuticals before rebranding in 2017.

David W. Pritchard

President and CEO and Board Member

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.